Evaluation of drug interactions in a large sample of psychiatric inpatients: A data interface for mass analysis with clinical decision support software

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 588-596

  Haueis, P ^a   Greil, W ^b   Huber, M ^a   Grohmann, R ^b   Kullak Ublick, G A ^a,c   Russmann, S ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; DOXEPIN; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HYDROCHLOROTHIAZIDE; LEVOMEPROMAZINE; LITHIUM; METOPROLOL; MOCLOBEMIDE; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENYTOIN; PIMOZIDE; POTASSIUM; RAMIPRIL; SOTALOL; SPIRONOLACTONE; THIORIDAZINE; TORASEMIDE; TRAMADOL; TRANYLCYPROMINE; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; BONE MARROW TOXICITY; CLINICAL DECISION MAKING; CLINICAL DECISION SUPPORT SOFTWARE; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INTERACTION; DRUG SAFETY; DRUG SCREENING; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPOTENSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MENTAL PATIENT; METABOLIC DISORDER; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CROSS-SECTIONAL STUDIES; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80052963501     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.150     Document Type: Article

References (32)

1. Gurwitz, J.H. et al. The incidence of adverse drug events in two large academic long-term care facilities. Am. J. Med. 118, 251-258 (2005). (Pubitemid 40312636)
2. C lassen, D.C., Pestotnik, S.L., Evans, R.S., Lloyd, J.F. & Burke, J.P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301-306 (1997). (Pubitemid 27045010)
3. Ernst, F.R. & Grizzle, A.J. Drug-related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc. (Wash). 41, 192-199 (2001).
4. Bates, D.W. et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274, 29-34 (1995).
5. Mojtabai, R. & Olfson, M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 67, 26-36 (2010).
6. Gurwitz, J.H. & Avorn, J. The ambiguous relation between aging and adverse drug reactions. Ann. Intern. Med. 114, 956-966 (1991).
7. Rothschild, J.M. et al. Medication safety in a psychiatric hospital. Gen. Hosp. Psychiatry 29, 156-162 (2007). (Pubitemid 46321635)
8. Kaushal, R., Shojania, K.G. & Bates, D.W. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch. Intern. Med. 163, 1409-1416 (2003). (Pubitemid 36758913)
9. Garg, A.X. et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA 293, 1223-1238 (2005). (Pubitemid 40327908)
10. Glassman, P.A., Simon, B., Belperio, P. & Lanto, A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med. Care 40, 1161-1171 (2002).
11. Hansten, P.D. Drug interaction management. Pharm. World Sci. 25, 94-97 (2003). (Pubitemid 36749799)
12. Shah, N.R. et al. Improving acceptance of computerized prescribing alerts in ambulatory care. J. Am. Med. Inform. Assoc. 13, 5-11 (2006). (Pubitemid 41828329)
13. Mannheimer, B., Ulfvarson, J., Eklöf, S., Bergqvist, M. & von Bahr, C. A clinical evaluation of the Janus Web Application, a software screening tool for drugdrug interactions. Eur. J. Clin. Pharmacol. 64, 1209-1214 (2008).
14. van der Sijs, H., Aarts, J., Vulto, A. & Berg, M. Overriding of drug safety alerts in computerized physician order entry. J. Am. Med. Inform. Assoc. 13, 138-147 (2006).
15. Weingart, S.N., Toth, M., Sands, D.Z., Aronson, M.D., Davis, R.B. & Phillips, R.S. Physicians' decisions to override computerized drug alerts in primary care. Arch. Intern. Med. 163, 2625-2631 (2003). (Pubitemid 37464421)
16. Lin, C.P., Payne, T.H., Nichol, W.P., Hoey, P.J., Anderson, C.L. & Gennari, J.H. Evaluating clinical decision support systems: monitoring CPOE order check override rates in the Department of Veterans Affairs' Computerized Patient Record System. J. Am. Med. Inform. Assoc. 15, 620-626 (2008).
17. Bergk, V., Gasse, C., Rothenbacher, D., Loew, M., Brenner, H. & Haefeli, W.E. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin. Pharmacol. Ther. 76, 85-96 (2004). (Pubitemid 38844737)
18. Hansten, P.D., Horn, J.R. & Hazlet, T.K. ORCA: OpeRational ClassificAtion of drug interactions. J. Am. Pharm. Assoc. (Wash). 41, 161-165 (2001).
19. Malone, D.C. et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J. Am. Pharm. Assoc. (2003). 44, 142-151 (2004).
20. Weih, M. et al. [Assessment of possible drug-drug interactions in psychopharmacotherapy after hospital discharge using an interactive database]. Fortschr. Neurol. Psychiatr. 79, 92-96 (2011).
21. Hansten, P.D. & Horn, J.R. Drug Interactions: Analysis and Management (Wolters Kluwer Health, Facts & Comparisons, St Louis, MO, 2010).
22. Lin, C.P. et al. Approach for analysis of order check overrides in a computerized practitioner order entry system. AMIA Annu. Symp. Proc. 1033 (2005).
23. Mallal, S. et al.; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008). (Pubitemid 351214284)
24. Fulda, T.R., Valuck, R.J., Vander Zanden, J., Parker, S., & Byrns, P.J. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr. Ther. Res. Clin. Exp. 61, 540-548 (2000).
25. Abarca, J. et al. Concordance of severity ratings provided in four drug interaction compendia. J. Am. Pharm. Assoc. (2003). 44, 136-141 (2004).
26. Vitry, A.I. Comparative assessment of four drug interaction compendia. Br. J. Clin. Pharmacol. 63, 709-714 (2007). (Pubitemid 46753565)
27. Smithburger, P.L., Kane-Gill, S.L., Benedict, N.J., Falcione, B.A. & Seybert, A.L. Grading the severity of drug-drug interactions in the intensive care unit: a comparison between clinician assessment and proprietary database severity rankings. Ann. Pharmacother. 44, 1718-1724 (2010).
28. Backman, J.T., Olkkola, K.T., Ojala, M., Laaksovirta, H. & Neuvonen, P.J. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37, 253-257 (1996). (Pubitemid 26071826)
29. MediQ. Psychiatrische Dienste Aargau AG, Brugg http://www.mediq.ch.
30. Grohmann, R., Engel, R.R., Rüther, E. & Hippius, H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37 (suppl. 1), S4-11 (2004).
31. Engel, R.R., Grohmann, R., Rüther, E. & Hippius, H. Research methods in drug surveillance. Pharmacopsychiatry 37 (suppl. 1), S12-S15 (2004). (Pubitemid 38658326)
32. Baxter, K. & Stockley, I.H. Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance, and Management 9th edn. (Pharmaceutical Press, London, 2010).